Jazz Pharmaceuticals CEO and Leadership

Bruce C. Cozadd co-founded Jazz Pharmaceuticals, Inc. in 2003 and has served as our Chairman and Chief Executive Officer since April 2009. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson, most recently as Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. Mr. Cozadd serves on the boards of two non-profit organizations, The Nueva School and SFJAZZ. He received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business.

Chris Tovey was appointed Executive Vice President, Chief Operating Officer and Managing Director, Europe & International, in May 2021 following the acquisition of GW Pharmaceuticals, where he served as EVP and Chief Operating Officer since joining the company in 2012. He applies over 30 years of commercial leadership and operations experience in the pharmaceutical industry to his role, where he oversees all Jazz commercial activities outside of North America, as well as global manufacturing and supply chain, and information technology and security. Mr. Tovey’s passion for patients fuels his enthusiasm and drive to find new and better ways to serve them, including work to develop and commercialize world-first breakthrough medicines.

Daniel N. Swisher, Jr. was appointed Jazz’s President in January 2018. Mr. Swisher has extensive experience in the advancement and commercialization of novel therapeutics across multiple therapeutic areas including neuroscience, metabolic, and targeted cancer agents. As President, he oversees the commercial and operating businesses, as well as research and development, and global product strategy and commercial development. Throughout his career, Mr. Swisher has exhibited and encouraged global operational excellence to foster innovation.

Proud to be a biotech leader for a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients. Currently serve as CFO of Jazz Pharmaceuticals and as a Board Member and Audit Chair for two growing life sciences companies. Experience in healthcare spans more than 20 years, leading teams in finance, corporate development, and strategy for several biopharmaceutical companies and serving on the boards of others. Skilled communicator with proven ability to drive results within large and small companies by building and developing high-performance teams, aligning and driving corporate strategy, solving complex problems, empowering leaders, and establishing transparent partnerships. Passionate about addressing equality and, specifically, improving gender diversity within the healthcare industry.

Heidi Manna is a Senior VP/Chief Human Resources Officer at Jazz Pharmaceuticals. She has experience at BRISTOL MYERS SQUIBB CO and has worked as VP:Human Resources at CAMPBELL SOUP CO. Heidi attended Binghamton University Foundation Housing Corp and State University of New York.

Neena M. Patil was appointed our Senior Vice President and General Counsel as of July 2019. From September 2018 to July 2019, Ms. Patil served as Senior Vice President, General Counsel and Corporate Secretary of Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company. Prior to that, from May 2008 to October 2016, Ms. Patil served in management positions at Novo Nordisk Inc., culminating in her role as Vice President for Legal Affairs and Associate General Counsel. Prior to 2008, she worked for several other global biopharmaceutical companies including Pfizer, GPC Biotech and Sanofi. Since 2015, she has been serving on the board of directors of Penn Medicine - Princeton Medical Center Foundation. Ms. Patil received a B.A. from Georgetown University and a J.D. and Master of Health Services Administration from the University of Michigan.

George Eliades, Ph.D., brings to Jazz significant global management consulting expertise from his 15 years of experience in Bain & Company’s Boston, Los Angeles, San Francisco and Zurich offices. During his tenure at Bain, he primarily advised clients in the biotech and pharmaceutical industries. Dr. Eliades has extensive experience supporting companies in oncology, neurology, endocrinology, ophthalmology and other specialty products. He brings deep experience in product launch and growth strategy, and the role of diagnostics and data in product strategy. Mr. Eliades is energized by the prospect of providing cures and treatments for devastating diseases to patients and their families.

Chris Tovey was appointed Executive Vice President, Chief Operating Officer and Managing Director, Europe & International, in May 2021 following the acquisition of GW Pharmaceuticals, where he served as EVP and Chief Operating Officer since joining the company in 2012. He applies over 30 years of commercial leadership and operations experience in the pharmaceutical industry to his role, where he oversees all Jazz commercial activities outside of North America, as well as global manufacturing and supply chain, and information technology and security. Mr. Tovey’s passion for patients fuels his enthusiasm and drive to find new and better ways to serve them, including work to develop and commercialize world-first breakthrough medicines.

Daniel N. Swisher, Jr. was appointed Jazz’s President in January 2018. Mr. Swisher has extensive experience in the advancement and commercialization of novel therapeutics across multiple therapeutic areas including neuroscience, metabolic, and targeted cancer agents. As President, he oversees the commercial and operating businesses, as well as research and development, and global product strategy and commercial development. Throughout his career, Mr. Swisher has exhibited and encouraged global operational excellence to foster innovation.